Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System

Neuroendocrine neoplasms (NENs) of the urinary bladder are rare but highly aggressive tumors that account for under 1% of bladder malignancies. The 2022 WHO classification recognizes small cell neuroe

Summary

A comprehensive state-of-the-art review by Anandi Lobo (Center for Pathology and Urology, Raipur) and Liang Cheng (Warren Alpert Medical School of Brown University & Lifespan Academic Medical Center) published in Endocrine Pathology (DOI: 10.1007/s12022-026-09932-0).

The review integrates histopathological, immunophenotypic, and genomic findings to address the fundamental shortcomings of the current 2022 WHO classification of urinary bladder neuroendocrine neoplasms (NENs). Because the WHO framework was directly extrapolated from gastroenteropancreatic and pulmonary models, it fails to account for unique bladder-specific biology — notably the overwhelming predominance of high-grade neuroendocrine carcinomas (NECs), their common clonal origin with conventional urothelial carcinoma (UC), and the practical absence of well-differentiated high-grade tumors (NET G3).

Lobo & Cheng formulate an organ-specific, refined 4-category classification system combining mitotic rate, Ki-67 proliferation index, morphology, and molecular drivers, while outlining emerging transcriptomic lineage subgroups (ASCL1, NEUROD1, POU2F3, triple-negative) and therapeutic horizons (DLL3-targeted bispecific T-cell engagers like tarlatamab).

The verbatim abstract is preserved in the description: frontmatter. The full text (23 pages, figures, tables, and 191 references) was reviewed from the version of record.

---

Why It Matters for Clinical & Surgical Pathology

1. Mandatory Reporting of Any Neuroendocrine Component: In bladder cancer, finding even minor focal small cell or large cell neuroendocrine carcinoma (<10%) radically alters clinical care. Standard transurethral resection (TURBT) or bladder-sparing gemcitabine-cisplatin regimens are inadequate; patients require systemic neoadjuvant chemotherapy (NAC) with platinum + etoposide (EP) prior to radical cystectomy due to extreme propensity for early micrometastatic dissemination.

2. Resolution of Diagnostic Traps:

   • TTF-1 (NKX2-1) is positive in 30–40% of primary bladder SCNECs! Pathologists who interpret TTF-1 positivity as proof of metastasis from small-cell lung cancer (SCLC) commit a critical misdiagnosis.

   • GATA3 is positive in 30–50% of bladder paragangliomas, which can lead to catastrophic confusion with muscle-invasive urothelial carcinoma if cytokeratins and neuroendocrine/sustentacular markers are omitted.

3. Anatomic Tie-Breaker via TERT Promoter Sequencing: When patients present with synchronous lung and bladder tumors, or concurrent prostatic and bladder masses, TERT promoter mutation testing (C228T / C250T) serves as a definitive bladder lineage discriminator: present in 70–80% of bladder SCNECs, but virtually absent in pulmonary SCLC and rare in prostatic small cell carcinoma.

---

Pathogenesis: Divergent Urothelial Lineage vs. Resident Cells

Historically debated whether bladder NENs arise from resident Kultschitzky-type neuroendocrine cells, metaplastic epithelium, or stem cells. Contemporary molecular biology strongly establishes divergent differentiation from transformed pluripotent urothelial stem cells:

• Frequent Co-existence: Over 50% of bladder SCNECs and LCNECs present with concurrent non-neuroendocrine components (conventional invasive UC, high-grade urothelial carcinoma in situ [CIS], squamous cell carcinoma, or adenocarcinoma).

• Shared Clonal Fingerprint: Laser-capture microdissection studies demonstrate that both components share identical loss-of-heterozygosity (LOH) patterns, identical TP53 mutations, identical RB1 deletions, and identical TERT promoter mutations.

• Contrast with Prostatic Neuroendocrine Carcinoma: In prostate cancer, neuroendocrine carcinoma predominantly emerges as a secondary, treatment-induced lineage plasticity switch under androgen receptor pathway inhibition (ARSI). In the bladder, SCNEC/LCNEC develops de novo or concurrently as part of primary clonal evolution, with no established treatment-emergent transdifferentiation paradigm following standard cytotoxic chemotherapy or immunotherapy.

---

Molecular Architecture & Driver Alterations

Genomic Landscape of Bladder Poorly Differentiated NECs
├── Dual Cell Cycle Inactivation (Obligate Hallmarks)
│   ├── TP53 Inactivation: >80–90% (missense/null mutations, LOH)
│   └── RB1 Inactivation: >70–80% (deletions, truncating mutations, loss of protein)
├── Urothelial Lineage Fingerprint
│   └── TERT Promoter Mutations (C228T, C250T): 70–80% (rare in lung SCLC or prostate small cell)
├── Mutational Signatures & Epigenetics
│   ├── APOBEC Mutational Signature (APOBEC3A/3B): High TMB, hypermutation
│   └── Chromatin Remodeling: ARID1A, KDM6A, KMT2C/D (MLL), CREBBP, EP300
└── Transcriptional Repression & Cell-Surface Targets
    └── Notch Pathway Suppression → Aberrant overexpression of DLL3 (Delta-like ligand 3)

---

Lobo & Cheng's Refined Bladder-Specific Classification

The authors propose a 4-tier organ-specific system tailored to bladder pathology (Table 2 in paper):

Category	Subclassification	Differentiation / Grade	Key Morphology	Mitotic Rate (per 2.5 mm²)	Ki-67 Index	Immunophenotype	Molecular Features	Clinical Behaviour
Well-Differentiated NETs	Bladder NET, G1	Well-differentiated, Low grade	Organoid nests, trabeculae, rosettes; bland cytology	< 2	$\le 3%$	Synaptophysin+, Chromogranin+, INSM1+	TP53 & RB1 intact	Indolent
	Bladder NET, G2	Well-differentiated, Intermediate grade	As above, with mild/moderate cytologic atypia	2–20	3–20%	Synaptophysin+, Chromogranin+, INSM1+	TP53 & RB1 intact	Intermediate
Poorly Differentiated NECs	Small Cell Neuroendocrine Carcinoma (SCNEC)	Poorly differentiated, High grade	Small cells, high N:C ratio, nuclear molding, crush artifact, necrosis	> 20	Usually > 60–70%	Synaptophysin+, INSM1+; Chromogranin variable; Keratin dot-like	Concurrent TP53 & RB1 biallelic inactivation; TERT promoter mut	Highly aggressive
	Large Cell Neuroendocrine Carcinoma (LCNEC)	Poorly differentiated, High grade	Large cells, abundant cytoplasm, prominent nucleoli, organoid/trabecular nesting, necrosis	> 20	> 40–50%	Synaptophysin+, Chromogranin+, INSM1+	Frequent TP53 and RB1 alterations; TERT mut	Highly aggressive
Mixed Neuroendocrine Neoplasms (MiNEN)	Bladder MiNEN	Mixed; driven by NE component	NEC or NET admixed with UC, adenocarcinoma, or squamous cell carcinoma	Variable	Variable	Respective markers positive in corresponding components	Shared clonal alterations (TERT, TP53, RB1)	Aggressive (dictated by NEC component)
Paraganglioma	Bladder PGL	Well-differentiated	Zellballen pattern of polygonal chief cells, delicate vascular network	< 2	< 3%	Synaptophysin+, Chromogranin+; S100/SOX10+ sustentacular; GATA3 +/-; Keratin negative	SDHB loss indicates germline SDHx syndromes	Indolent

The Critical Omission: Why "NET G3" Does Not Belong in the Bladder

In the pancreas and digestive tract, NET G3 represents a well-differentiated tumor with organoid morphology, intact TP53/RB1, but elevated Ki-67 (>20%). In the urinary bladder, rigorous review of published literature and institutional series identifies no reproducible cases of true NET G3. Every bladder tumor exhibiting Ki-67 >20% and high mitotic activity shows the cytologic features, mutational profile (TP53 and RB1 co-inactivation), and aggressive clinical course of a poorly differentiated NEC (SCNEC or LCNEC). Retaining a NET G3 category in the bladder risks undertreating aggressive NECs with indolent somatostatin analogue protocols.

---

Four Lineage Transcription Factor Subtypes in Bladder NECs

Paralleling the molecular classification of pulmonary small-cell carcinoma (SCLC-A, SCLC-N, SCLC-P, SCLC-I), bladder SCNEC and LCNEC harbor four distinct lineage subsets:

1. ASCL1-Dominant (SCLC-A): Classic high-neuroendocrine phenotype with robust neuroendocrine granules, high Synaptophysin/Chromogranin expression, and elevated DLL3 levels.

2. NEUROD1-Dominant (SCLC-N): Intermediate neuroendocrine profile, frequent neuronal differentiation programs.

3. POU2F3-Dominant (SCLC-P): Tuft cell-like differentiation. Tumors are often negative or weak for conventional neuroendocrine markers (Synaptophysin/Chromogranin negative, but positive for POU2F3 and GFI1B). Demonstrates significantly shorter progression-free survival (PFS) and overall survival (OS), representing an ultra-aggressive variant.

4. Triple-Negative / Inflamed (SCLC-I): Low expression of all three master transcription factors. Characterized by mesenchymal transitions, HLA upregulation, and dense immune infiltration — representing the primary candidate subset for immune checkpoint blockade.

---

Immunohistochemical Diagnostic Workup & Traps

Differential Diagnosis	Recommended IHC Panel	Diagnostic Clues & Pitfalls
Primary Bladder SCNEC vs. Metastatic Lung SCLC	INSM1, Synaptophysin, Chromogranin, TTF-1, GATA3, CK903, TERT promoter NGS	TTF-1 is positive in 30–40% of bladder SCNECs (cannot rule out bladder primary). TERT promoter mutation (C228T/C250T) is positive in ~80% of bladder SCNECs, negative in lung SCLC.
Bladder SCNEC vs. Prostatic Small Cell Carcinoma	PSA, PSMA, NKX3.1, AR, ERG, GATA3, TERT promoter NGS	Prostatic small cell is frequently negative for PSA/PSMA/NKX3.1 due to dedifferentiation. TERT promoter mutation confirms bladder urothelial lineage; prostate SCNEC lacks TERT mutations.
Bladder SCNEC vs. High-Grade Urothelial Carcinoma	INSM1, Synaptophysin, GATA3, p63, RB1	High-grade UC can focally express neuroendocrine markers. INSM1 provides crisp nuclear specificity. Complete loss of RB1 strongly supports SCNEC.
Paraganglioma vs. Invasive Urothelial Carcinoma	Pancytokeratin (AE1/AE3, CAM5.2), GATA3, Synaptophysin, Chromogranin, S100, SOX10, SDHB	GATA3 is positive in 30–50% of paragangliomas! Cytokeratin is strictly negative in paraganglioma. S100/SOX10 highlights peripheral sustentacular meshwork. SDHB loss alerts for germline SDHx testing.

---

Therapeutic Horizons & The Immunotherapy Paradox

• Neoadjuvant Platinum-Etoposide (EP): Standard of care for muscle-invasive or high-risk bladder SCNEC prior to radical cystectomy.

• The Immunotherapy Paradox: Bladder SCNEC exhibits high tumor mutational burden (TMB) driven by APOBEC cytidine deaminases, yet immune checkpoint inhibitor (ICI) monotherapy has shown disappointing clinical activity. Histopathologically, the tumor microenvironment is an "immune desert" or "immune excluded" niche with low PD-L1 expression (0–50%), dense peritumoral extracellular matrix, and scarce intratumoral CD8+ T-cell infiltration.

• Ineffectiveness of Bladder UC ADCs: Enfortumab vedotin (targeting Nectin-4) and Sacituzumab govitecan (targeting TROP2) have low or absent target expression in pure SCNEC.

• DLL3-Targeted Precision Therapy (Tarlatamab): Downregulation of Notch signaling causes high cell-surface expression of Delta-like ligand 3 (DLL3). Following the landmark success of tarlatamab (bispecific T-cell engager / BiTE targeting DLL3 and CD3; demonstrated dramatic overall survival improvements in SCLC in DeLLphi-301 and Phase 3 DeLLphi-304), DLL3 represents the most promising biomarker-driven target for bladder SCNEC.